MYEF2

Across TCGA pan-cancer cohorts, MYEF2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYEF2 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MYEF2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYEF2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and OV show a favorable association.

DLBC, UCEC, and OV are the cancer types where MYEF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
UCEC	DFS	Median	All	0.944	0.613	.007	18	view →
OV	DFS	Median	III,IV	1.000	0.150	.020	12	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYEF2–DLBC (DFS)

Open the DLBC breakdown →